Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer Progression Early Access Programs and Physician Onboarding Initiatives Expected to Begin in Early 2026 UNIONDALE, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Proteomic Panel,” has been published online in Clinical and Tra ...

Core Insights - Caris Life Sciences has identified TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors [1][3] - The study, led by Dr. Padmanee Sharma, utilized TET2-mutant laboratory models to explore how these mutations influence immune dynamics within the tumor microenvironment [2] - The research analyzed outcomes from nearly 36,000 non-small cell lung cancer (NSCLC) patients and over 25,000 colorectal cancer (CRC) patients, providing substantial evidence supporting TET2-CH as a potential biomarker for enhanced ICI response [3] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI applications [6] - The company has created a large-scale, multimodal clinico-genomic database to analyze the molecular complexity of diseases, enhancing early detection, diagnosis, monitoring, therapy selection, and drug development [6][7] - Caris operates internationally with offices in multiple locations, including the U.S., Japan, and Switzerland, and aims to realize the potential of precision medicine to improve human health [7]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance Biotherapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period from May 9, 2024, to May 8, 2025 [1][6]. Company Summary - Iovance Biotherapeutics, Inc. is facing scrutiny following a class action complaint filed on May 15, 2025, which claims that the company provided misleading statements regarding its growth potential and was not adequately prepared to meet demand for its treatments [1][6]. - The company announced its financial results for Q2 of fiscal 2024 on July 25, 2024, and subsequently lowered its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance issues and lower-than-expected sales [6]. - Following the announcement of reduced guidance, Iovance's stock price experienced a significant decline, dropping from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decrease of approximately 44.8% in just one day [6].

SOURCE Rigel Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED Accessibility StatementSkip Navigation SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live ...

Core Insights - Legend Biotech Corporation will host a conference call on November 12, 2025, at 8:00 am ET to discuss its third quarter 2025 results [1] - The company is a leader in cell therapy, particularly known for its CAR-T cell therapy product, CARVYKTI, for treating relapsed or refractory multiple myeloma [3] Company Overview - Legend Biotech employs over 2,800 individuals and is recognized as the largest standalone cell therapy company [3] - The company collaborates with Johnson & Johnson to develop and market CARVYKTI, aiming to enhance patient access and therapeutic potential [3] - Legend Biotech is focused on expanding its leadership in the cell therapy sector and driving future innovations across its pipeline [3]

Core Insights - Immutep Limited is advancing its clinical trials for eftilagimod alfa (efti) in oncology and autoimmune diseases, with significant progress reported in multiple trials [2][3][31] Oncology Development Programs - The TACTI-004 (KEYNOTE-F91) Phase III trial for advanced non-small cell lung cancer (NSCLC) is ongoing, with over 100 clinical sites activated across 24 countries, aiming to enroll approximately 756 patients [3][4] - The trial has successfully enrolled and randomized over 170 patients, surpassing the number required for a futility analysis, which is expected to be completed in Q1 CY2026 [6] - Positive feedback from the FDA has been received regarding the late-stage clinical development of efti for head and neck cancer patients with low PD-L1 expression [9][11] - The INSIGHT-003 Phase I trial is also evaluating efti in combination with KEYTRUDA® and chemotherapy for non-squamous NSCLC, with data presented at ESMO 2025 [7][8] Soft Tissue Sarcoma and Breast Cancer Trials - The EFTISARC-NEO Phase II trial for soft tissue sarcoma has met its primary endpoint, showing significant tumor hyalinization compared to historical data [16] - The AIPAC-003 trial for metastatic breast cancer has enrolled 71 patients, with ongoing follow-up and data analysis expected to be reported at the San Antonio Breast Cancer Symposium in December 2025 [17][19] Financial Position - As of September 30, 2025, Immutep reported a strong cash position of approximately A$109.85 million, consisting of A$83.41 million in cash and cash equivalents and A$26.44 million in term deposits [27] - The net cash used in R&D activities during Q1 FY26 was A$15.83 million, reflecting increased clinical trial activities [28] Intellectual Property Developments - Immutep was granted four new patents during the quarter, enhancing its intellectual property portfolio related to LAG-3 and its therapeutic applications [24]

Interim Data for KYSA-6 Phase 2 Clinical Trial of KYV-101 in Generalized Myasthenia Gravis Conference Call October 29, 2025 Cindy MG Warrior Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the "Company"). All statements other than statements of historical facts contained in this presentation are forw ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [2][8]. Group 1: Company Overview - Maravai LifeSciences Holdings, Inc. is facing legal scrutiny following a class action complaint filed on March 3, 2025, concerning events from August 7, 2024, to February 24, 2025 [2]. - The company announced a postponement of its fiscal 2024 earnings release and a delay in filing its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [8]. Group 2: Financial Impact - Following the announcement of the revenue recognition error, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [8]. - The class action complaint alleges that the company made materially false and misleading statements regarding its financial health, including inadequate internal controls over financial reporting and overstated goodwill [8]. Group 3: Legal Actions - Investors who purchased Maravai stock during the specified class period are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and options [1][4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about these claims [4].

Core Insights - Purple Biotech has achieved a commercially viable yield for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, positioning the program competitively for future development [1] - The CAPTN-3 platform has been validated for scalability, indicating its potential for developing complex tri-specific antibodies with competitive yield and purity [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [3] - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [3] Technology and Mechanism - The CAPTN-3 platform generates conditionally activated tri-specific antibodies that engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment [2][3] - The technology incorporates a cleavable capping mechanism that confines therapeutic activity to the tumor microenvironment, potentially increasing the therapeutic window for patients [2][3] Clinical Development - An Investigational New Drug (IND) submission for IM1240 is planned for 2026, with the antibody advancing toward first-in-human clinical trials [1] - NT219 has demonstrated anti-tumor activity in combination with cetuximab in a Phase 1 study and is currently being evaluated in a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4]

JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the sec ...